Prentiss Smith & Co. Inc. Has $2.38 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Prentiss Smith & Co. Inc. trimmed its holdings in Agilent Technologies, Inc. (NYSE:A) by 3.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,054 shares of the medical research company’s stock after selling 586 shares during the quarter. Agilent Technologies comprises about 1.5% of Prentiss Smith & Co. Inc.’s portfolio, making the stock its 26th biggest position. Prentiss Smith & Co. Inc.’s holdings in Agilent Technologies were worth $2,384,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in A. Crewe Advisors LLC increased its position in Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after buying an additional 101 shares in the last quarter. Ridgewood Investments LLC bought a new stake in Agilent Technologies during the 2nd quarter worth approximately $29,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Agilent Technologies in the second quarter valued at approximately $39,000. Riverview Trust Co bought a new position in shares of Agilent Technologies in the first quarter valued at approximately $41,000. Finally, Larson Financial Group LLC grew its holdings in shares of Agilent Technologies by 29,300.0% in the first quarter. Larson Financial Group LLC now owns 294 shares of the medical research company’s stock valued at $43,000 after acquiring an additional 293 shares in the last quarter. 87.42% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at $3,497,110. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,953 shares of company stock worth $2,013,630. Insiders own 0.33% of the company’s stock.

Agilent Technologies Stock Down 1.5 %

A traded down $2.06 on Monday, hitting $136.77. The company had a trading volume of 313,714 shares, compared to its average volume of 1,682,754. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. Agilent Technologies, Inc. has a 52-week low of $96.80 and a 52-week high of $155.35. The stock has a fifty day simple moving average of $141.02 and a 200-day simple moving average of $138.73. The firm has a market capitalization of $39.90 billion, a P/E ratio of 32.82, a P/E/G ratio of 6.96 and a beta of 1.05.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same period last year, the business posted $1.43 earnings per share. Agilent Technologies’s quarterly revenue was down 5.6% compared to the same quarter last year. As a group, equities analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st will be issued a $0.236 dividend. The ex-dividend date of this dividend is Tuesday, October 1st. This represents a $0.94 annualized dividend and a yield of 0.69%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on A shares. UBS Group upped their price objective on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Wells Fargo & Company started coverage on Agilent Technologies in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price objective on the stock. Bank of America upped their price objective on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Barclays increased their target price on Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a research report on Tuesday, October 15th. Finally, Evercore ISI upped their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $144.36.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.